Home › Funds › ORBIMED ADVISORS LLC › CRNX

ORBIMED ADVISORS LLC position in CRNX

CRINETICS PHARMACEUTICALS IN

ORBIMED ADVISORS LLC reported holding 999,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$37.4M, representing 0.75% of its reported portfolio and ranking #37 among its reported holdings. ORBIMED ADVISORS LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)999.00K sh
Reported value held$37.38M
Portfolio Weight0.75%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's CRNX position evolved

ORBIMED ADVISORS LLC first disclosed a stake in CRNX in Q3 2023 at 2,896,074 shares (US$86.1M). Across 12 filings, ORBIMED ADVISORS LLC increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 999,000 shares valued at US$37.4M. Notable position changes include a 42% trim in Q4 2023, a 91% trim in Q3 2025, a 899% increase in Q4 2025.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.90M $86.13M New
Q4 2023 1.67M $59.32M Reduce
Q1 2024 1.39M $64.83M Reduce
Q2 2024 1.28M $57.37M Reduce
Q3 2024 1.05M $53.66M Reduce
Q4 2024 999.00K $51.08M Reduce
Q1 2025 999.00K $33.51M Hold
Q2 2025 1.15M $33.05M Add
Q3 2025 100.00K $4.17M Reduce
Q4 2025 999.00K $46.50M Add
Q1 2026 999.00K $36.28M Hold
Q2 2026 999.00K $37.38M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held CRNX?

ORBIMED ADVISORS LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ORBIMED ADVISORS LLC's current position in CRNX?

As of Q2 2026, ORBIMED ADVISORS LLC holds 999.00K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $37.38M, representing 0.75% of its reported portfolio and ranking #37.

Has ORBIMED ADVISORS LLC been buying or selling CRNX?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in CRNX.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.